Non-Small Cell Lung Cancer

For this analysis, investigators were interested in patient non–small cell lung cancer (NSCLC)–related outcomes from antibiotic administration before immunotherapy alone or immunotherapy and chemotherapy.

Patients were satisfied with receiving their lung cancer screening (LCS) pulmonary nodule results via letter and considered the amount of information provided in the letter appropriate.

This new analysis incorporated 1997-2013 data on patients with a history of surgical resection of stage IIIA-N2 non-small cell lung cancer (NSCLC) and their postop complications to evaluate the possibility of better identifying future surgical candidates.

Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for non–small cell lung cancer (NSCLC).

In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.

The complete response letter (CRL) was not related to safety or efficacy data, but was a result of inspection findings at a third-party manufacturing facility.

“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”

This investigation sought to expand knowledge of the impact of comorbid pulmonary hypertension (PH) on diagnosed non–small cell lung cancer (NSCLC), using data from adult patients treated at military hospital facilities within the US.

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) in the phase 3 FLAURA2 study.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.

This investigation sprung from a lack of current knowledge on the impact of nonmalignant results following thoracic surgery for lung cancer, according to the authors.

Data presented at the recent American Thoracic Society 2024 international conference identified the top barriers to lung cancer screening in Asian Americans, and common risk factors among this population.

This qualitative study on primary care physicians yielded suggestions that can inform the design of an effective lung cancer screening decision aid tool and implementation into the electronic health record.

This international study, incorporating data from the US, Brazil, Singapore, and Spain, shows that durvalumab as maintenance therapy for use against non–small cell lung cancer remains a cost-prohibitive treatment option.

For this analysis of how body composition might affect the impact of immunotherapy used to treat non–small cell lung cancer (NSCLC), investigators from Dana-Farber Brigham Cancer Center compared patient outcomes based on baseline body composition measurements or first follow-up scan.

Investigators continue to seek more information on how to optimally integrate treatment with tyrosine kinase inhibitors (TKIs) into an established concurrent chemoradiotherapy regimen.

Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.

Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.

This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.

For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.

Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy.

The data for this analysis on survivors of lung cancer came from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center thoracic oncology clinics.

Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.